Eliane Schutte is Xeltis Chief Executive Officer since 2018. Under her leadership, the company expanded its strategy into vascular and valve applications, closed a €10.5 million Series D financing round in 2019, secured €15 million financing from the European Investment Bank and €15 million funding from the European Union in 2021. At Xeltis since 2015 as Chief Development Officer, she led the clinical trial program, product development strategy and regulatory.
Eliane has extensive expertise in global product development and regulatory affairs, with over 20 years in the medtech and biotech industries. Prior to Xeltis, she was Vice President for global product development in peri-operative care at The Medicines Company, Chief Development Officer at Dutch-US biotech start-up Profibrix and Vice President for regulatory affairs and EU operations at IsoTis Orthobiologics.
Eliane was included in the list of The Top 50 Healthcare Technology CEOs by the Healthcare Technology Report in 2021 and 2022.